| 发明名称 |
ANTIBODY THAT BINDS CD269 (BCMA) SUITABLE FOR USE IN THE TREATMENT OF PLASMA CELL DISEASES SUCH AS MULTIPLE MYELOMA AND AUTOIMMUNE DISEASES |
| 摘要 |
The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases. |
| 申请公布号 |
US2015284467(A1) |
申请公布日期 |
2015.10.08 |
| 申请号 |
US201314440165 |
申请日期 |
2013.11.01 |
| 申请人 |
MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN |
发明人 |
Lipp Martin;Oden Felix;Höpken Uta;Müller Gerd;Daumke Oliver;Marino Stephen;Olal Daniel |
| 分类号 |
C07K16/28;A61K47/48;C07K16/30 |
主分类号 |
C07K16/28 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. Isolated antibody or antibody fragment that binds CD269 (BCMA), wherein the antibody binds an epitope comprising one or more amino acids of residues 13 to 32 (SEQ ID No. 14) of CD269. |
| 地址 |
Berlin DE |
